-
Mashup Score: 0
Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally tolerated it well, according to data published in The Lancet Respiratory Medicine.“Vanzacaftor-tezacaftor-deutivacaftor was safe and well tolerated and maintained FEV1 percent predicted from elexacaftor/tezacaftor/ivacaftor baseline with further improved CFTR
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 1
Among patients with COPD who experienced an exacerbation, the risk for cardiovascular events was highest in the following 2 weeks and stayed elevated more than 1 year after, according to study results.These findings were published in American Journal of Respiratory and Critical Care Medicine.
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
Published in @ATSBlueEditor: Among patients with #COPD who experienced an #exacerbation, the risk for #cardiovascular events❤️ was highest in the following 2 weeks and stayed elevated more than 1 year after. @CardiologyToday Read more⬇️ https://t.co/8pU3IQvHuH
-
-
Mashup Score: 1
Among patients with COPD who experienced an exacerbation, the risk for cardiovascular events was highest in the following 2 weeks and stayed elevated more than 1 year after, according to study results.These findings were published in American Journal of Respiratory and Critical Care Medicine.
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
Published in @ATSBlueEditor: Among patients with #COPD who experienced an #exacerbation, the risk for #cardiovascular events❤️ was highest in the following 2 weeks and stayed elevated more than 1 year after. @CardiologyToday Read more⬇️ https://t.co/8pU3IQvHuH
-
-
Mashup Score: 0Pneumonia | Free Clinical Guidance | Healio - 2 day(s) ago
Access free, up-to-date clinical guidance on pneumonia at Healio. We offer valuable insights for identifying, assessing, treating, and managing this condition.
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
Check out Clinical Guidance’s new #pneumonia module, where you can quickly read up on the virus’s presentation, how to confirm diagnosis and more: https://t.co/NOFe1t6p0w https://t.co/RiEnRPe5sL
-
-
Mashup Score: 4
A smaller proportion of women vs. men underwent lung transplantation, plus women spent a longer time on the wait list before receiving the transplant, according to results published in ERJ Open Research.“Clinicians, patients and policymakers must acknowledge this gender difference as it’s essential for appropriate action to be taken,” Adrien Tissot, MD, from Nantes University
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
Published in @ERSpublications: A smaller proportion of women👩 vs. men👨 underwent #lung #transplantation, plus women spent a longer time⏰ on the wait list. ➕ @fatimaanjum28, MD, MHA, @templemedschool, shares her Perspective. Read more⬇️ https://t.co/Ql4uqUYGdI
-
-
Mashup Score: 4
A smaller proportion of women vs. men underwent lung transplantation, plus women spent a longer time on the wait list before receiving the transplant, according to results published in ERJ Open Research.“Clinicians, patients and policymakers must acknowledge this gender difference as it’s essential for appropriate action to be taken,” Adrien Tissot, MD, from Nantes University
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
Published in @ERSpublications: A smaller proportion of women👩 vs. men👨 underwent #lung #transplantation, plus women spent a longer time⏰ on the wait list. ➕ @fatimaanjum28, MD, MHA, @templemedschool, shares her Perspective. Read more⬇️ https://t.co/Ql4uqUYGdI
-
-
Mashup Score: 0Q&A: ‘Dawn of a new era for OSA care’ moving into 2025 - 6 day(s) ago
Entering 2025, adults with moderate to severe obstructive sleep apnea and obesity have a new FDA-approved treatment option that takes the form of a GIP/GLP-1 dual agonist, according to a press release from Eli Lilly and Company.Researchers observed that tirzepatide (Zepbound, Eli Lilly) reduced apnea-hypopnea index (AHI) events per hour and led to greater weight loss at 1 year vs. placebo in two
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
❗In a new Q&A, Healio spoke with Larry Miller, MD, CEO of @apnimed, to learn more about #obesity and #neuromuscular dysfunction in patients with #OSA😴, the use of #GLP-1s in OSA care and trials assessing AD109. #sleep Read more⬇️ https://t.co/tya1QNLMzJ
-
-
Mashup Score: 0Q&A: ‘Dawn of a new era for OSA care’ moving into 2025 - 6 day(s) ago
Entering 2025, adults with moderate to severe obstructive sleep apnea and obesity have a new FDA-approved treatment option that takes the form of a GIP/GLP-1 dual agonist, according to a press release from Eli Lilly and Company.Researchers observed that tirzepatide (Zepbound, Eli Lilly) reduced apnea-hypopnea index (AHI) events per hour and led to greater weight loss at 1 year vs. placebo in two
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
❗In a new Q&A, Healio spoke with Larry Miller, MD, CEO of @apnimed, to learn more about #obesity and #neuromuscular dysfunction in patients with #OSA😴, the use of #GLP-1s in OSA care and trials assessing AD109. #sleep Read more⬇️ https://t.co/tya1QNLMzJ
-
-
Mashup Score: 0Vanzacaftor, tezacaftor, deutivacaftor similar to current cystic fibrosis standard of care - 7 day(s) ago
Among individuals aged at least 12 years with cystic fibrosis, receipt of vanzacaftor/tezacaftor/deutivacaftor was similar or better than Trikafta depending on the endpoint, according to results published in The Lancet Respiratory Medicine.“These results demonstrate the potential for vanzacaftor-tezacaftor-deutivacaftor to further improve the lives of people with cystic fibrosis by limiting
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
Published in @LancetRespirMed📣: Among individuals aged at least 12 years with #CysticFibrosis, receipt of vanzacaftor/tezacaftor/deutivacaftor (#Alyftrek, @VertexPharma) was similar or better than #Trikafta depending on the endpoint. Read more⬇️ https://t.co/ZCB4buHoto
-
-
Mashup Score: 0Vanzacaftor, tezacaftor, deutivacaftor similar to current cystic fibrosis standard of care - 7 day(s) ago
Among individuals aged at least 12 years with cystic fibrosis, receipt of vanzacaftor/tezacaftor/deutivacaftor was similar or better than Trikafta depending on the endpoint, according to results published in The Lancet Respiratory Medicine.“These results demonstrate the potential for vanzacaftor-tezacaftor-deutivacaftor to further improve the lives of people with cystic fibrosis by limiting
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
Published in @LancetRespirMed📣: Among individuals aged at least 12 years with #CysticFibrosis, receipt of vanzacaftor/tezacaftor/deutivacaftor (#Alyftrek, @VertexPharma) was similar or better than #Trikafta depending on the endpoint. Read more⬇️ https://t.co/ZCB4buHoto
-
Published in @LancetRespirMed📣: Patients aged 6 to 11 years with #CysticFibrosis receiving 24-week once-daily #vanzacaftor/#tezacaftor/#deutivacaftor generally tolerated it well. #Alyftrek @VertexPharma Read more⬇️ https://t.co/KWMBiwjNwB